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Abstract Since the beginning of the 1990s, Japanese
medical practitioners have extensively prescribed angioten-
sin-converting enzyme (ACE) inhibitors for children with
mild IgA nephropathy (IgA-N) and steriods for those with
severe IgA-N. We have performed a retrospective cohort
study to clarify whether the long-term outcome has
improved in Japanese children with IgA-N. Renal survival
was defined as the time from onset to end-stage renal
disease (ESRD). We divided the study period into two time
periods based on the occurrence of the initial renal
biopsy:1976–1989 and 1990–2004. Actuarial survivals
were calculated by Kaplan–Meier method, and comparisons
were made with the logrank test. The Cox proportional
hazard model was used for multivariate analysis. Between
1976 and 2004, 500 children were diagnosed as having
IgA-N in our hospitals. The actuarial renal survival from
the time of apparent disease onset was 96.4% at 10 years,
84.5% at 15 years and 73.9% at 20 years. Renal survival in
the 1990–2004 period was significantly better than that in
1976–1989 (p=0.008), and a marked improvement in renal
survival in patients with severe IgA-N was also observed
(p=0.0003). Multivariate analysis indicated that diagnosis
year was a significant factor for ESRD-free survival
independently of baseline characteristics. The results of
this study show that there has been an improvement in
terms of renal survival in Japanese children with IgA-N.
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Introduction
IgA nephropathy (IgA-N) is the most common primary
glomerulonephritis worldwide. It was initially considered to
be a benign disease with a favorable prognosis, but data from
long-term follow-up studies subsequently revealed that the
disease progressed to renal failure in 20–50% of adult
patients [1, 2]. Although there has been a prevailing belief
that the prognosis of IgA-N is more benign in children, the
results of more recent studies do not support this [3]. At the
beginning of the 1990s, a strict policy of treatment for IgA-
N was adopted by the majority of physicians [4]; this
consisted of the extensive use of angiotensin-converting
enzyme inhibitors (ACEIs) as an almost universally used
therapy for IgA-N, and other therapies, including cortico-
steroids, for more severe IgA-N [4]. This approach has also
been adopted in Japan since the beginning of the 1990s,
with ACEIs generally prescribed for children with mild
IgA-N showing focal mesangial proliferation and steroids
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Setagaya, Tokyo, Japanprescribed for children with severe IgA-N showing diffuse
mesangial proliferation. Combined therapy with predniso-
lone, azathioprine, heparin–warfarin and dipyridamole for 2
years in patients with severe IgA-N showing diffuse
mesangial proliferation was started at the Kobe University
and Wakayama Medical University hospitals in 1990 [5, 6].
At present, the effect of this therapy on long-term renal
survival in children with IgA-N remains unknown as there
have been few studies on outcome in sufficiently large
cohorts of pediatric patients [4].
In the study reported here, we investigated data from 500
children with IgA-N to determine whether the long-term
outcome has improved in Japanese children with IgA-N.
Methods
Patients
The medical history of children under the age of 20
years who underwent routine renal biopsies at Kobe
University and Wakayama Medical University hospitals
between January 1976 and December 2004 were ana-
lyzed retrospectively. Clinical data and follow-up infor-
mation were obtained from the medical records, and if
needed, further complementary information was obtained
by telephone contact with the patients, family members
and or physicians.
A diagnosis of IgA-N was based on the presence of IgA
as the sole or predominant immunoglobulin in the glomer-
ular mesangium in the absence of systemic disease [7].
Diffuse or focal mesangial proliferation was defined on the
basis of World Health Organization criteria [8]: diffuse
mesangial proliferation was defined as more than 80% of
glomeruli showing moderate or severe mesangial cell
proliferation, i.e. more than three cells per peripheral
mesangial area; focal mesangial proliferation was defined
as less than 80% of glomeruli showing moderate or severe
mesangial cell proliferation. All children with IgA-N were
diagnosed by one investigator (N.Y.) using the same criteria
during the entire study period. Renal biopsies were
performed in children with persistent proteinuria (early
morning urine protein/creatinine ratio ≥0.2g/g) with or
without hematuria. Renal biopsy criteria were not changed
during the entire study period.
Renal survival was defined as the period from the time
of apparent disease onset to end-stage renal disease (ESRD)
requiring renal replacement therapy.
Given the change of policy for treating IgA-N patients in
the early 1990s, we divided the study period when the
initial renal biopsy had been performed into two time
periods: 1976–1989 (early period) and 1990–2004 (late
period).
Treatment
Since we started a strict policy of treatment for IgA-N at the
beginning of the 1990s, we investigated the initial treatment
profile of children with IgA-N. After a pilot study period,
we started the first randomized controlled trial (RCT) by
the Japanese Pediatric IgA Nephropathy Treatment Study
Group (JPIGANTS) for treatment of children with severe
IgA-N showing diffuse mesangial proliferation in 1990 [5].
We started the second RCT by the JPIGANTS for treatment
of children with severe IgA-N in 1994 [6]. We started the
third RCT by the JPIGANTS for treatment of children with
severe IgA-N in 2001. The details of each treatment are
shown in Table 1.
For the treatment of children with mild IgA-N showing
focal mesangial proliferation we started a RCT by the
JPIGANTS in 1990. During this trial (1990–1993) about
half of the children with mild IgA-N in our hospitals
received Sairei-to, a Chinese herb, for 24 months, and the
other half received no medication. We began to use ACEIs
for treatment of mild IgA-N with focal mesangial prolifer-
ation as the first choice from the beginning of 2000.
Statistical analyses
The results were analyzed with SAS ver. 9.1.2 (SAS
Institute Japan Ltd., Tokyo, Japan). The associations
between categorical variables were examined using the
Fisher’s exact test. Continuous characteristics of the groups
were compared with the Mann-Whitney U-test. Actuarial
survival curves were calculated according to the Kaplan-
Meier method [9], and comparisons were made with the
logrank test [10]. Univariate and multivariate analyses were
performed to assess the difference between the two periods
in terms of renal survival. For multivariate analysis, we
used the Cox proportional hazard model [11]. A two-tailed
p value of less than 0.05 was taken as the level of
significance.
Results
Patients
Between 1976 and 2004, 1759 children underwent a first
renal biopsy examination at the Kobe University and
Wakayama Medical University hospitals. Among these,
500 Japanese children (28.4%; 279 boys and 221 girls)
were diagnosed as having IgA-N: 219 in 1976–1989 and
281 in 1990–2004. There was no evident change in the
number of patients per year between the early (1976–1989)
and late (1990–2004) periods. The median patient age at
diagnosis was 10.9 years (range 2.5–19.6 years), and the
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years (range 1.3–20.5 years).
The baseline characteristics of children with IgA-N are
shown in Table 2. There were significant differences in
some characteristics between the two periods. Age at
diagnosis had a tendency to be higher in the late group,
while the ratio of asymptomatic proteinuria and hematuria
at initial presentation was significantly higher in the late
group. The ratio of heavy proteinuria (≥ 1 g/m
2 per day) at
diagnosis was significantly higher in the early period, but
the ratio of patients showing diffuse mesangial proliferation
was higher in the late period. Based on these data, we
Table 2 Baseline characteristics
Characteristic Number of patients (%) p
Total (n=500) 1976–1989 (n=219) 1990–2004 (n=281)
Sex (M/F) 279/221 132/87 147/134 0.08
Age at diagnosis, year, median [range] 10.9 [2.5–19.6] 10.1 [3.4–16.8] 11.6 [2.5–19.6] < 0.001
Initial presentation
Asymptomatic proteinuria and hematuria 384 (76.8%) 150 (68.5%) 234 (83.3%) < 0.001
Macroscopic hematuria 93 (18.6%) 60 (27.4%) 33 (11.7%) < 0.001
Edema 23 (4.6%) 9 (4.1%) 14 (5.0%) 0.67
Proteinuria at diagnosis (g/m
2/day)
<1 361 (72.2%) 146 (66.7%) 215 (76.5%) 0.008
≥1 139 (27.8%) 73 (33.3%) 66 (23 .5%)
Estimate creatinine clearance at diagnosis (ml/min per 1.73 m
2)
<60 13 (2.6%) 3 (1.4%) 10 (3.6%) 0.16
≥60 487 (97.4%) 216 (98.6%) 271 (96.4%)
Renal biopsy at diagnosis
Diffuse mesangial proliferation 171 (34.2%) 63 (28.8%) 108 (38.4%) 0.03
Focal mesangial proliferation 329 (65.8%) 156 (71.2%) 173 (61.6%)
Table 1 Treatment in three randomized controlled trials for childhood IgA nephropathy with diffuse mesangial proliferation
Period 1990–1993 (first RCT) 1994–1998 (second RCT) 2001–present (third RCT)
Group 1 Prednisolone Prednisolone (as in group 1 in the first period) Prednisolone
2 mg/kg/day, 4 weeks 2 mg/kg/day, 4 weeks
2 mg/kg/2 days, 4 weeks 2 mg/kg/2 days, 4 weeks
1.5 mg/kg/2 days, 4 weeks 1.5 mg/kg/2 days, 4 weeks
1 mg/kg/2 days, 21 months 1 mg/kg/2 days, 9 months
0.5 mg/kg/2 days, 12 months
Azathioprine Azathioprine (as in group 1 in the first period) No azathioprine
2 mg/kg/day, 24 months
Dipyridamole Dipyridamole (as in group 1 in the first period) Dipyridamole
5 mg/kg/day, 24 months 6–7 mg/kg/day, 24 months
Heparin No heparin
APTT 60 s, 28 days
Warfarin Warfarin Warfarin
TT 30–50%, 23 months TT 30–50%, 24 months TT 20–50%, 24 months
Mizoribine
4 mg/kg/day, 24 months
Group 2 Heparin-Warfarin
Dipyridamole (as in group 1)
Prednisolone (as in group 1) Prednisolone (as in group 1)
Mizoribine (as in group 1)
TT, Thrombotest; APTT, activated partial thromboplastin time; RCT, randomized controlled trial
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severity between the two periods.
Treatment
The initial treatment for IgA-N showing focal mesangial
proliferation or diffuse mesangial proliferation is given in
detail in Table 3. There was a clear change of treatment for
IgA-N between the early and late periods. This is
particularly true in terms of ACEI use for focal mesangial
proliferation and combined therapies for diffuse mesangial
proliferation, both of which increased dramatically during
the late period.
Renal survival
Among a total of 500 patients who had IgA-N therapy, the
actuarial renal survival from the time of apparent disease
onset was 96.4% at 10 years, 84.5% at 15 years and 73.9%
at 20 years (Table 4). As shown in Fig. 1 and Table 4,i n
children diagnosed as having IgA-N in 1976–1989, the
actuarial renal survival from the time of apparent disease
onset was 94.0% at 10 years, 80.1% at 15 years and 70.1%
at 20 years. In children diagnosed as having IgA-N in
1990–2004, the actuarial renal survival from the time of
apparent disease onset was 98.8% at 10 years, 98.8% at 15
years (p=0.008; Fig. 1, Table 4).
Figures 2 and 3 show the long-term outcome for children
in the two different mesangial proliferation groups. For
children with severe IgA-N showing diffuse mesangial
proliferation, both the 10- and 13-year renal survivals were
97.8% when the diagnosis was made in the period 1990–
2004; when the diagnosis was made in the period 1976–
1989, renal survivals were 78.5% and 68.6%, respectively
(p=0.0003; Fig. 2, Table 4). For children with mild IgA-N
showing focal mesangial proliferation, both the 10- and 15-
year renal survivals were 100.0% when diagnosis was made
in 1990–2004, compared with 100.0% and 97.7%, respec-
tively, in 1976–1989 (p=0.5; Fig. 3, Table 4). Although we
observed better renal survival in patients diagnosed in the
period 1990–2004 than in the period 1976–1989 for
children with IgA-N showing focal mesangial proliferation,
the difference did not reach statistical significance. The
children with IgA-N showing diffuse mesangial prolifera-
tion in 1990–2004 had excellent long-term renal survival.
Table 5 shows the results of the univariate analysis using
the logrank test and the multivariate analysis using the Cox
proportional hazard model of prognostic factors for ESRD-
Table 4 Actuarial renal survival analysis of 500 children with IgA nephropathy
Initial renal
biopsy year
Number of
patients
10-year renal
survival
15-year renal
survival
20-year renal
survival
p
a
Total 1976–2004 500 96.4% 84.5% 73.9%
Total 1976–1989 219 94.0% 80.1% 70.1% 0.008
1990–2004 281 98.8% 98.8% –
Diffuse mesangial proliferation 1976–1989 63 78.5% 68.6%
b – 0.0003
1990–2004 108 97.8% 97.8%
b –
Focal mesangial proliferation 1976–1989 156 100.0% 97.7% – 0.5
1990–2004 173 100.0% 100.0% –
ap values on the logrank test
bThe 13-year survival
Table 3 Change of initial treatment for IgA nephropathy in Japanese children
Treatment Focal mesangial proliferation Diffuse mesangial proliferation
1976–1989
(n=156)
1990–2004
(n=173)
1976–1989
(n=63)
1990–2004
(n=108)
No treatment 96 (61.6%) 23 (13.2%) 19 (30.2%) 1 (0.9%)
Antiplatelet and/or anticoagulant 35 (22.4%) 2 (1.2%) 14 (22.2%) 7 (6.5%)
Prednisolone, (± antiplatelet and/or anticoagulant) 4 (2.6%) 6 (3.5%) 7 (11.1%) 25 (23.1%)
Prednisolone + immunosuppressant, (± antiplatelet and/or anticoagulant) 7 (4.5%) 8 (4.6%) 19 (30.2%) 74 (68.5%)
Chinese herb (Sairei-to) 14 (9.0%) 46 (26.5%) 4 (6.3%) 0 (0.0%)
ACEI and/or ARB 0 (0.0%) 88 (50.9%) 0 (0.0%) 1 (0.9%)
ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker
908 Pediatr Nephrol (2008) 23:905–912free survival. Mesangial proliferation degree (focal or
diffuse), proteinuria at diagnosis (<1 or ≥1 g/m
2 per day),
estimate of creatinine clearance at diagnosis (≥60 or
<60 ml/min per 1.73 m
2) and initial renal biopsy
(diagnosis) year (1976–1989 or 1990–2004) were includ-
ed as factors for analyses. Mesangial proliferation degree
and initial renal biopsy year were significant in both the
univariate and the multivariate analysis. For children with
IgA-N, the most influential prognostic variable was
mesangial proliferation degree. Proteinuria at diagnosis
was significant in the univariate but not in the multivariate
analysis. These results from the multivariate analysis
showed that initial renal biopsy year was a significant
factor for ESRD-free survival independently of mesangial
proliferation degree, proteinuria at diagnosis and estimate
of creatinine clearance at diagnosis (hazard ratio = 0.08,
95% CI 0.004–0.43; Table 5).
Discussion
Although this was a retrospective study, the data seem to
provide unique and valuable information about IgA-N in
children for several reasons. First, the study subjects were
a complete non-selected cohort of patients with IgA-N
from among all children who underwent first renal biopsy
examinations at Kobe University and Wakayama Medical
University hospitals between 1976 and 2004. Five
hundred children with IgA-N participated in our study,
which to our knowledge is the largest series used to
investigate the outcome of IgA-N in children to date.
Furthermore, these patients were diagnosed histologically
by a single investigator (N.Y.) based on the same criteria
during the whole study period. Renal biopsy criteria were
also unchanged during the whole study period. Therefore,
the cohort in the present study is considered to have been
rigidly homogeneous in terms of the analysis of the
disease outcome.
One of the conditions that facilitated our study was the
school screening program, which was started by the
Japanese government in 1974. In Japan, all children
between the ages of 6 and 18 years are screened annually,
and those found to have urinary abnormalities are referred
for further investigation. Thus, in general, treatment for
IgA-N is started early in the course of disease because the
duration of disease before treatment is short as a result of
this school screening program [12]. Therefore, in this study
we were able to observe the disease courses of patients
during the initial renal biopsy period, 1976–2004, who
underwent initial treatments for IgA-N at a relatively
homogeneous stage of the disease. Accumulated experience
indicates that long-term corticosteroid and/or immunosup-
pressive treatment during the severely progressive stage of
the disease does not confer any benefit in adult patients [2].
Fig. 3 Kaplan-Meier plot of renal survival stratified by the initial
biopsy year for children with mild IgA nephropathy showing focal
mesangial proliferation
Fig. 2 Kaplan-Meier plot of renal survival stratified by the initial
biopsy year for children with severe IgA nephropathy showing diffuse
mesangial proliferation
Fig. 1 Kaplan–Meier plot of renal survival stratified by the initial
biopsy year for children with IgA nephropathy. 95% CI 95%
Confidence interval
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urine screening programs are more likely to diagnose mild
disease with a good prognosis, thus favorably influencing
the overall outcome of the cohort [13].
Another favorable parameter of this study was the
enforcement of consecutive systemic nationwide clinical
trials of IgA-N. After a pilot study period, the first RCT for
treatment of children with severe IgA-N showing diffuse
mesangial proliferation was started by the JPIGANTS in
1990 [5]. To date, two RCTs of treatment for children with
severe IgA-N showing diffuse mesangial proliferation by
the JPIGANTS have been completed [5, 6], and the third
RCT of treatment for children with severe IgA-N showing
diffuse mesangial proliferation is currently being conducted
by the same group. For the treatment of children with mild
IgA-N and focal mesangial proliferation, a RCT was also
started by the JPIGANTS in 1990. After completion of the
RCT, we have conducted prospective clinical trials of
treatment for children with mild IgA-N and focal mesangial
proliferation. These prospective trials have enabled for us to
clarify the optimum treatment for IgA-N and to collect
precise information on patients with IgA-N.
Because of the variable rate of progression to renal
failure and the probable multifactorial pathogenesis of IgA-
N, it is desirable to evaluate the effectiveness of any
treatment by a prospective controlled trial. However,
although the ultimate endpoint in any clinical trial of
progressive IgA-N is the development of chronic renal
insufficiency, most pediatric patients do not develop it
during the study period [14]. Therefore, data from a
properly analyzed long-term retrospective study may also
be important to evaluate disease outcome and treatment
effectiveness [4, 9–11]. Retrospective studies with accurate
statistical evaluation using life-time analysis and multivar-
iate survivorship analysis according to the Cox regression
model are thought to work effectively together with well-
designed RCTs.
The primary purpose of this study was to clarify whether
long-term outcome was improved in Japanese children with
IgA-N retrospectively using adequate statistical methods.
Although it seemed that there were no clinically significant
differences in the baseline characteristics of the groups,
there were some statistically significant differences in the
baseline characteristics of the groups between the two
periods when initial renal biopsies were performed. These
different baseline characteristics may influence the final
outcomes reported in this study. To compensate for this
limitation, we used a multivariate survivorship analysis
according to the Cox regression model. Since we have to
adjust for differences of baseline characteristics, which
were thought to be important prognostic factors [15],
mesangial proliferation degree, proteinuria at diagnosis,
estimate of creatinine clearance at diagnosis and the initial
renal biopsy (diagnosis) year were included as factors for
analyses. This multivariate analysis indicated that the initial
renal biopsy year was a significant factor for ESRD-free
survival after adjustment of these baseline characteristics.
These data support an improvement of renal survival in
Japanese children with IgA-N.
There was a notable lack of the usual dominance of
males over females in our study and, in addition, there
was a difference between the 1976–1989 and the 1990–
2004 periods, with more females being recruited in the
second period. Although this difference was not statis-
tically significant (p=0.08), we decided that it be
worthwhile discussing possible reasons for the differ-
ences in gender representation between the two periods.
Therefore, we analyzed males and females separately.
However, there was no gender-based factor in the results
(data not shown).
At the beginning of the 1990s, a strict policy of
treatment was adopted by the majority of physicians in
Japan. It is likely that therapeutic intervention early after
the onset of clinically apparent disease will provide the best
opportunity for improving the outcome of patients with
IgA-N, thus reducing the number of patients who develop
ESRD [5, 6]. This study showed a clear change in the
treatment of IgA-N between the early and late groups
(Table 3). In particular, the use of ACEIs for focal
mesangial proliferation and combination therapies for
diffuse mesangial proliferation increased dramatically in
the late group.
Table 5 Univariate and multivariate analysis of the prognostic value of factors for end-stage renal disease-free survival
Factor Univariate Multivariate
HR 95% CI p HR 95% CI p
Mesangial proliferation focal; diffuse 10.92 2.80–72.46 <0.001 10.27 2.42–70.75 0.001
Proteinuria at diagnosis <1; ≥1 (g/m
2/day) 5.27 1.65–19.77 0.01 2.14 0.57–8.78 0.26
CCl at diagnosis ≥ 60; < 60 (ml/min per m
2) 14.12 2.11–57.41 0.01 5.58 0.74–30.22 0.09
Initial renal biopsy year 1976–1989; 1990–2004 0.14 0.01–0.74 0.02 0.08 0.004–0.43 0.002
CI, Confidence interval; HR, hazard ratio; CCl, creatinine clearance
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to severe IgA-N, particularly in pediatric patients. Some
evidence has been obtained recently pertaining to the role
of corticosteroids in the treatment of IgA-N [2, 13, 14, 16–
18]. With regard to children and based on the results of two
multicenter RCTs, we reported previously that the treatment
of childhood IgA-N with diffuse mesangial proliferation
using prednisolone, azathioprine, warfarin and dipyrida-
mole for 2 years early in the course of disease reduced the
severity of immunologic renal injury and prevented any
increase in the percentage of sclerosed glomeruli [5, 6]. In
contrast, in the first RCT, heparin–warfarin and dipyrida-
mole treatments for 2 years did not reduce urinary protein
excretion, serum IgA concentration and mesangial IgA
deposition, and they did not prevent any increase of
sclerosed glomeruli [5]. The results of the second RCT
showed that the treatment of children with severe IgA-N
using prednisolone alone for 2 years reduced the severity of
immunologic renal injury, but did not prevent any further
increase of glomerular sclerosis [6]. Therefore, treatment
with the combination therapy using prednisolone and
immunosuppressant, such as azathioprine, may be better
than the prednisolone monotherapy for patients with severe
IgA-N.
We found an improvement of long-term renal survival in
Japanese children with IgA-N (Table 4, Figs. 1 and 2).
Renal survival in 1990–2004 was significantly better than
in 1976–1989 (Fig. 1), and a marked improvement of renal
survival in IgA-N showing diffuse mesangial proliferation
was observed over time (Fig. 2). This improvement may be
related to the 2-year therapy, including corticosteroids, for all
patients with IgA-N showing diffuse mesangial proliferation
as a treatment policy, although in principle the effectiveness
of any treatment can only be evaluated properly by a
controlled trial. It is conceivable that the outcome in the
period 1976–1989 may have reflected the natural course of
disease, whereas that in 1990–2004 may have reflected
modification of the disease course by the treatments.
The median follow-up period of the patients overall was
5.9 years (range 1.3–20.5 years). Although this is a
considerably long period, it may not be sufficiently long
for the follow-up of IgA-N, which has a slow progressive
course. Since the elapsed time from apparent disease onset
to ESRD was used to evaluate the disease outcome, chronic
renal insufficiency before ESRD was not considered in our
study. Thus, we do not know whether the observed
improvement of outcome means a complete cure of the
disease or merely a delay of the disease course. Further
follow-up of the cohort for a long period is therefore
important.
One aspect which we should consider in our study is the
possibility that at least some of the differences in outcome
between the early and late groups may be due to general
changes in care that have occurred over time. Such changes
are frequently not recognized, such as a gradually greater
awareness of managing marginally raised blood pressure,
among others.
In conclusion, this study has demonstrated a substantial
improvement of long-term renal survival in Japanese
children with IgA-N. On the basis of the results of this
study we were unable to provide the reason for this
improved outcome directly; however, it is likely that
adequate management using a strict policy of treatment
may have been responsible.
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